Prezista®
Company
Tibotec Pharmaceuticals, Ltd.
Use
Treatment of patients with HIV-1 strains resistant to more than one protease inhibitor
Features
Second-generation protease inhibitor that overcomes resistance to older agents in this class
NIH Contribution
Robust HIV protease inhibitor
Approval Type
FDA
HHS Institute/Agency
NCI
Inventor(s)
J. Erickson
Year
2006
Tech Cat
Therapeutic
